Chemistry

AKT drives SOX2 overexpression and most cancers cell stemness in esophageal most cancers by defending SOX2 from UBR5-mediated degradation


1.

Sarkar A, Hochedlinger Okay. The sox household of transcription components: versatile regulators of stem and progenitor cell destiny. Cell Stem Cell. 2013;12:15–30.

2.

Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B. Management of cell destiny and differentiation by Sry-related high-mobility-group field (Sox) transcription components. Int J Biochem Cell Biol. 2007;39:2195–214.

three.

Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi Okay, et al. Pluripotency ruled by Sox2 through regulation of Oct3/four expression in mouse embryonic stem cells. Nat Cell Biol. 2007;9:625–35.

four.

Arnold Okay, Sarkar A, Yram MA, Polo JM, Bronson R, Sengupta S, et al. Sox2(+) grownup stem and progenitor cells are vital for tissue regeneration and survival of mice. Cell Stem Cell. 2011;9:317–29.

5.

Wuebben EL, Rizzino A. The darkish facet of SOX2: most cancers – a complete overview. Oncotarget. 2017;eight:44917–43.

6.

Weina Okay, Utikal J. SOX2 and most cancers: present analysis and its implications within the clinic. Clin Transl Med. 2014;three:19.

7.

Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–42.

eight.

Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.three amplifications in human lung squamous cell carcinomas. PLoS ONE. 2010;5:e8960.

9.

Gen Y, Yasui Okay, Zen Y, Zen Okay, Dohi O, Endo M, et al. SOX2 recognized as a goal gene for the amplification at 3q26 that’s steadily detected in esophageal squamous cell carcinoma. Most cancers Genet Cytogenet. 2010;202:82–93.

10.

Most cancers Genome Atlas Analysis Community; Evaluation Working Group; Asan College; BC Most cancers Company; Brigham and Ladies’s Hospital; Broad Institute et al. Built-in genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–75.

11.

Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, Mikut R, et al. SOX2 amplification is a typical occasion in squamous cell carcinomas of various organ websites. Hum Pathol. 2011;42:1078–88.

12.

Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, et al. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS ONE. 2011;6:e26740.

13.

Tam WL, Ng HH. Sox2: masterminding the foundation of most cancers. Most cancers Cell. 2014;26:three–5.

14.

Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, et al. Quiescent sox2(+) cells drive hierarchical development and relapse in sonic hedgehog subgroup medulloblastoma. Most cancers Cell. 2014;26:33–47.

15.

Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes cease of proliferation and lack of tumorigenicity. Stem Cells. 2009;27:40–48.

16.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate most cancers. Science. 2017;355:84–88.

17.

Liu Okay, Jiang M, Lu Y, Chen H, Solar J, Wu S, et al. Sox2 cooperates with inflammation-mediated Stat3 activation within the malignant transformation of foregut basal progenitor cells. Cell Stem Cell. 2013;12:304–15.

18.

Gen Y, Yasui Okay, Nishikawa T, Yoshikawa T. SOX2 promotes tumor development of esophageal squamous cell carcinoma by way of the AKT/mammalian goal of rapamycin complicated 1 signaling pathway. Most cancers Sci. 2013;104:810–6.

19.

Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. SOX2 controls tumour initiation and most cancers stem-cell capabilities in squamous-cell carcinoma. Nature. 2014;511:246–50.

20.

Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer Okay, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to provoke mesenchymal stem cell reprogramming towards Ewing sarcoma most cancers stem cells. Genes Dev. 2010;24:916–32.

21.

Mayer IA, Arteaga CL. The PI3K/AKT pathway as a goal for most cancers therapy. Annu Rev Med. 2016;67:11–28.

22.

Jeong CH, Cho YY, Kim MO, Kim SH, Cho EJ, Lee SY, et al. Phosphorylation of Sox2 cooperates in reprogramming to pluripotent stem cells. Stem Cells. 2010;28:2141–50.

23.

Fang L, Zhang L, Wei W, Jin X, Wang P, Tong Y, et al. A methylation-phosphorylation change determines Sox2 stability and performance in ESC upkeep or differentiation. Mol Cell. 2014;55:537–51.

24.

Siegel RL, Miller KD, Jemal A. Most cancers Statistics, 2017. CA Most cancers J Clin. 2017;67:7–30.

25.

Hirai H, Sootome H, Nakatsuru Y, Miyama Okay, Taguchi S, Tsujioka Okay, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by normal chemotherapeutic brokers or molecular focused medication in vitro and in vivo. Mol Most cancers Ther. 2010;9:1956–67.

26.

Barsyte-Lovejoy D, Li F, Oudhoff MJ, Tatlock JH, Dong A, Zeng H, et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase exercise in cells. Proc Natl Acad Sci USA. 2014;111:12853–eight.

27.

Cox JL, Wilder PJ, Gilmore JM, Wuebben EL, Washburn MP, Rizzino A. The SOX2-interactome in mind most cancers cells identifies the requirement of MSI2 and USP9X for the expansion of mind tumor cells. PLoS ONE. 2013;eight:e62857.

28.

Wang H, Paczulla AM, Konantz M, Lengerke C. In vitro tumorigenic assay: the tumor spheres assay. Strategies Mol Biol. 2018;1692:77–87.

29.

Lu YX, Yuan L, Xue XL, Zhou M, Liu Y, Zhang C, et al. Regulation of colorectal carcinoma stemness, development, and metastasis by an miR-200c-Sox2-negative suggestions loop mechanism. Clin Most cancers Res. 2014;20:2631–42.

30.

Ozen M, Karatas OF, Gulluoglu S, Bayrak OF, Sevli S, Guzel E, et al. Overexpression of miR-145-5p inhibits proliferation of prostate most cancers cells and reduces SOX2 expression. Most cancers Make investments. 2015;33:251–eight.

31.

Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137:647–58.

32.

Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung most cancers. Mol Most cancers. 2012;11:73.

33.

Peltier J, Conway A, Keung AJ, Schaffer DV. Akt will increase sox2 expression in grownup hippocampal neural progenitor cells, however elevated sox2 doesn’t promote proliferation. Stem Cells Dev. 2011;20:1153–61.

34.

Zhang HF, Wu C, Alshareef A, Gupta N, Zhao Q, Xu XE, et al. The PI3K/AKT/c-MYC axis promotes the acquisition of most cancers stem-like options in esophageal squamous cell carcinoma. Stem Cells. 2016;34:2040–51.

35.

Fang X, Yoon JG, Li L, Tsai YS, Zheng S, Hood L, et al. Panorama of the SOX2 protein-protein interactome. Proteomics. 2011;11:921–34.

36.

Callaghan MJ, Russell AJ, Woollatt E, Sutherland GR, Sutherland RL, Watts CK. Identification of a human HECT household protein with homology to the Drosophila tumor suppressor gene hyperplastic discs. Oncogene. 1998;17:3479–91.

37.

Saunders DN, Hird SL, Withington SL, Dunwoodie SL, Henderson MJ, Biben C, et al. Edd, the murine hyperplastic disc gene, is crucial for yolk sac vascularization and chorioallantoic fusion. Mol Cell Biol. 2004;24:7225–34.

38.

Shearer RF, Iconomou M, Watts CK, Saunders DN. Practical roles of the E3 ubiquitin ligase UBR5 in most cancers. Mol Most cancers Res. 2015;13:1523–32.

39.

Meissner B, Kridel R, Lim RS, Rogic S, Tse Okay, Scott DW, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood. 2013;121:3161–four.

40.

Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa Okay, et al. Glioma-initiating cells retain their tumorigenicity by way of integration of the Sox axis and Oct4 protein. J Biol Chem. 2011;286:41434–41.

41.

Basu-Roy U, Web optimization E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene. 2012;31:2270–82.

42.

Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga Okay, et al. Sox2 expression in breast tumours and activation in breast most cancers stem cells. Oncogene. 2012;31:1354–65.

43.

Gupta N, Gopal Okay, Wu C, Alshareef A, Chow A, Wu F, et al. Phosphorylation of Sox2 at threonine 116 is a possible marker to establish a subset of breast most cancers cells with excessive tumorigenecity and stem-like options. Cancers (Basel). 2018; 10. https://doi.org/10.3990/cancers10020041.

44.

Zhang J, Gao Q, Li P, Liu X, Jia Y, Wu W, et al. S phase-dependent interplay with DNMT1 dictates the position of UHRF1 however not UHRF2 in DNA methylation upkeep. Cell Res. 2011;21:1723–39.


Supply hyperlink
asubhan

wordpress autoblog

amazon autoblog

affiliate autoblog

wordpress web site

web site improvement

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close